516 related articles for article (PubMed ID: 32905851)
1. SARS-CoV-2 infections in children and young people.
Felsenstein S; Hedrich CM
Clin Immunol; 2020 Nov; 220():108588. PubMed ID: 32905851
[TBL] [Abstract][Full Text] [Related]
2. Cross-reactive memory T cells and herd immunity to SARS-CoV-2.
Lipsitch M; Grad YH; Sette A; Crotty S
Nat Rev Immunol; 2020 Nov; 20(11):709-713. PubMed ID: 33024281
[TBL] [Abstract][Full Text] [Related]
3. COVID-19 herd immunity: where are we?
Fontanet A; Cauchemez S
Nat Rev Immunol; 2020 Oct; 20(10):583-584. PubMed ID: 32908300
[TBL] [Abstract][Full Text] [Related]
4. What about the original antigenic sin of the humans versus SARS-CoV-2?
Roncati L; Palmieri B
Med Hypotheses; 2020 Sep; 142():109824. PubMed ID: 32408068
[No Abstract] [Full Text] [Related]
5. Remodeling of the Immune Response With Aging: Immunosenescence and Its Potential Impact on COVID-19 Immune Response.
Cunha LL; Perazzio SF; Azzi J; Cravedi P; Riella LV
Front Immunol; 2020; 11():1748. PubMed ID: 32849623
[TBL] [Abstract][Full Text] [Related]
6. Keeping track of the SARS-CoV-2 vaccine pipeline.
Parker EPK; Shrotri M; Kampmann B
Nat Rev Immunol; 2020 Nov; 20(11):650. PubMed ID: 32989290
[TBL] [Abstract][Full Text] [Related]
7. Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries.
Kwok KO; Lai F; Wei WI; Wong SYS; Tang JWT
J Infect; 2020 Jun; 80(6):e32-e33. PubMed ID: 32209383
[No Abstract] [Full Text] [Related]
8. Exploring uncertainty and risk in the accelerated response to a COVID-19 vaccine: Perspective from the pharmaceutical industry.
Coudeville L; Gomez GB; Jollivet O; Harris RC; Thommes E; Druelles S; Chit A; Chaves SS; Mahé C
Vaccine; 2020 Nov; 38(48):7588-7595. PubMed ID: 33097312
[TBL] [Abstract][Full Text] [Related]
9. Not just antibodies: B cells and T cells mediate immunity to COVID-19.
Cox RJ; Brokstad KA
Nat Rev Immunol; 2020 Oct; 20(10):581-582. PubMed ID: 32839569
[TBL] [Abstract][Full Text] [Related]
10. Coronavirus reinfections: three questions scientists are asking.
Ledford H
Nature; 2020 Sep; 585(7824):168-169. PubMed ID: 32887957
[No Abstract] [Full Text] [Related]
11. BCG revaccination of health workers in Brazil to improve innate immune responses against COVID-19: A structured summary of a study protocol for a randomised controlled trial.
Junqueira-Kipnis AP; Dos Anjos LRB; Barbosa LCS; da Costa AC; Borges KCM; Cardoso ADRO; Ribeiro KM; Rosa SBA; Souza CC; das Neves RC; Saraiva G; da Silva SM; Silveira EA; Rabahi MF; Conte MB; Kipnis A
Trials; 2020 Oct; 21(1):881. PubMed ID: 33106170
[TBL] [Abstract][Full Text] [Related]
12. Emergence, Transmission, and Potential Therapeutic Targets for the COVID-19 Pandemic Associated with the SARS-CoV-2.
Patil AM; Göthert JR; Khairnar V
Cell Physiol Biochem; 2020 Aug; 54(4):767-790. PubMed ID: 32830930
[TBL] [Abstract][Full Text] [Related]
13. Exploring the out of sight antigens of SARS-CoV-2 to design a candidate multi-epitope vaccine by utilizing immunoinformatics approaches.
Safavi A; Kefayat A; Mahdevar E; Abiri A; Ghahremani F
Vaccine; 2020 Nov; 38(48):7612-7628. PubMed ID: 33082015
[TBL] [Abstract][Full Text] [Related]
14. COVID-19 in Africa: Dampening the storm?
Mbow M; Lell B; Jochems SP; Cisse B; Mboup S; Dewals BG; Jaye A; Dieye A; Yazdanbakhsh M
Science; 2020 Aug; 369(6504):624-626. PubMed ID: 32764055
[No Abstract] [Full Text] [Related]
15. Vaccines targeting SARS-CoV-2 tested in humans.
Edwards KM
Nat Med; 2020 Sep; 26(9):1336-1338. PubMed ID: 32839620
[No Abstract] [Full Text] [Related]
16. Caregiver willingness to vaccinate their children against COVID-19: Cross sectional survey.
Goldman RD; Yan TD; Seiler M; Parra Cotanda C; Brown JC; Klein EJ; Hoeffe J; Gelernter R; Hall JE; Davis AL; Griffiths MA; Mater A; Manzano S; Gualco G; Shimizu N; Hurt TL; Ahmed S; Hansen M; Sheridan D; Ali S; Thompson GC; Gaucher N; Staubli G;
Vaccine; 2020 Nov; 38(48):7668-7673. PubMed ID: 33071002
[TBL] [Abstract][Full Text] [Related]
17. COVID-19 vaccine and boosted immunity: Nothing ad interim to do?
Roncati L; Vadalà M; Corazzari V; Palmieri B
Vaccine; 2020 Nov; 38(48):7581-7584. PubMed ID: 33071005
[TBL] [Abstract][Full Text] [Related]
18. The paramount importance of serological surveys of SARS-CoV-2 infection and immunity.
Goudsmit J
Eur J Epidemiol; 2020 Apr; 35(4):331-333. PubMed ID: 32318914
[No Abstract] [Full Text] [Related]
19. SARS - CoV-2: Reasons of epidemiology of severe ill disease cases and therapeutic approach using trivalent vaccine (tetanus, diphtheria and Bordetella pertussis).
Ietto G
Med Hypotheses; 2020 Aug; 141():109779. PubMed ID: 32387756
[TBL] [Abstract][Full Text] [Related]
20. Controlled, double-blind, randomized trial to assess the efficacy and safety of hydroxychloroquine chemoprophylaxis in SARS CoV2 infection in healthcare personnel in the hospital setting: A structured summary of a study protocol for a randomised controlled trial.
Cuadrado-Lavín A; Olmos JM; Cifrian JM; Gimenez T; Gandarillas MA; García-Saiz M; Rebollo MH; Martínez-Taboada V; López-Hoyos M; Fariñas MC; Crespo J
Trials; 2020 Jun; 21(1):472. PubMed ID: 32493494
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
